Table 1.
Demographic details including biochemical, hematologic indices, and use of medication
| PD (n = 53) | HD (n = 62) | P Value | |
|---|---|---|---|
| Age (yr) | 62.5 ± 13.1 | 65.3 ± 15.5 | NS |
| Male (%) | 31 (58%) | 34 (55%) | NS |
| White ethnicity | 49 (92%) | 56 (90%) | NS |
| Diabetes mellitus | 7 (13%) | 6 (10%) | NS |
| Smoking | 3 (6%) | 5 (8%) | NS |
| Dialysis vintage (mo) | 38.4 ± 14.3 | 51.7 ± 34.7 | 0.007 |
| Body mass index (kg/m2) | 26 ± 3 | 27 ± 5 | NS |
| Dialysis adequacy (Kt/V)a | 2.4 ± 0.08 | 1.25 ± 0.18 | NA |
| Previous cardiovascular morbidityb | 6 (11%) | 8 (13%) | NS |
| Total cholesterol (mM) | 4.6 ± 1.0 | 4.4 ± 1.0 | NS |
| HDL cholesterol (mM) | 1.4 ± 0.3 | 1.3 ± 0.3 | NS |
| LDL cholesterol (mM) | 2.2 ± 1.1 | 2.0 ± 0.8 | NS |
| Triglycerides (mM) | 2.2 ± 0.8 | 2.4 ± 1.8 | NS |
| Serum phosphate (mM) | 1.52 ± 0.2 | 1.64 ± 0.4 | NS |
| Serum corrected calcium (mM) | 2.51 ± 0.1 | 2.47 ± 0.1 | NS |
| Calcium × phosphate product (mmol2/L2) | 4.03 ± 0.7 | 4.21 ± 1.0 | NS |
| PTH (pg/ml) | 342 ± 301 | 298 ± 313 | NS |
| Albumin (g/L) | 29.7 ± 3.7 | 32.5 ± 3 | NS |
| Hemoglobin (g/dl) | 12.0 ± 1.14 | 11.8 ± 1.56 | NS |
| Lipid-lowering therapy | 29 (55%) | 27 (44%) | NS |
| Use of calcium channel blockers | 5 (9%) | 6 (10%) | NS |
| Use of ACE inhibitors | 19 (36%) | 9 (15%) | 0.006 |
| Use of β blockers | 3 (6%) | 5 (8%) | NS |
| Use of erythropoietin | 46 (87%) | 56 (90%) | NS |
| Skin autofluourescence (AU) | 3.58 ± 0.75 | 3.7 ± 0.88 | NS |
There were no significant differences in patient characteristics, apart from dialysis vintage and use of angiotensin-converting enzyme inhibitors (ACEi).
NS, not significant; NA, not applicable.
a
Kt/V is weekly in PD and per session in HD.
b
Defined as any previous description of ischemic heart disease, heart failure, cerebrovascular disease, or peripheral vascular disease.